TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04054661

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HemoCue System
Description: The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
Study: NCT03985709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic product
Description: Probiotic (Lactobacillus casei) once daily taken by 3 months.
Study: NCT04517994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Treatment
Description: See arm description.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Treatment
Description: See arm description.
Study: NCT02228811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-2701 tablet
Study: NCT03243656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eltrombopag
Description: An oral thrombopoietin receptor agonist
Study: NCT02303769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin HCL 0.4mg
Description: Tamsulosin HCL 0.4mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin HCL 0.2mg
Description: Tamsulosin HCL 0.2mg once a day
Study: NCT04744792

Intervention type: OTHER
Intervention: WHODAS-II
Description: The World Health Organization disability assessment schedule II (WHODAS-II)~The WHODAS-II is an instrument developed by the World Health Organization to assess behavioral limitations and restrictions regarding participation in specific activity domains experienced by an individual independent of their medical diagnosis. The conceptual frame of reference of this instrument is the International Classification of Functioning, Disability, and Health (ICF). Specifically, the instrument is a 36-item, generic, multidimensional questionnaire designed to evaluate the functioning of the individual in six activity domains (i.e., understanding and communicating, getting around, self-care, getting along with people, life activities, and participation in society). This questionnaire has been validated in Turkish patients.

Intervention type: OTHER
Intervention: WHODAS-II
Description: The World Health Organization disability assessment schedule II (WHODAS-II)~The WHODAS-II is an instrument developed by the World Health Organization to assess behavioral limitations and restrictions regarding participation in specific activity domains experienced by an individual independent of their medical diagnosis. The conceptual frame of reference of this instrument is the International Classification of Functioning, Disability, and Health (ICF). Specifically, the instrument is a 36-item, generic, multidimensional questionnaire designed to evaluate the functioning of the individual in six activity domains (i.e., understanding and communicating, getting around, self-care, getting along with people, life activities, and participation in society). This questionnaire has been validated in Turkish patients.
Study: NCT02162238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LSF-filtering device
Description: Device: LSF-filtering device LifeStraw Family is a water purification device that by means of hollow fibres removes solid particles (\<0.5 Nephelometric Turbidity units turbidity reduction), bacteria (\>Log 6 reduction), viruses (\>Log 4 reduction) and cysts (\>Log 3 reduction). Zinc enrichment is provided by a chamber housing a zinc releasing glass-plate that is placed annexed to the hollow fibre column. It is estimated that the LSF can provide about 5 mg of zinc/l of filtered water. By consuming daily a portion of 0.6 litres of enriched water, \>100% of the age-specific estimated physiologic requirement would be covered, assuming a fractional absorption of 40%.
Study: NCT03529864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Study: NCT00589732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan 160mg per day
Study: NCT02846415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play Intervention for Dementia
Description: 1. 8 weekly session, 45-75 minutes each~2. Play with toys~3. Sessions will be facilitated by a play specialist, trained play assistants, and centre staff.
Study: NCT02293421

Intervention type: OTHER
Group type: OTHER
Intervention: Obstructive sleep apnea
Study: NCT00814281

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: 10 mg ingested orally 1 hour prior to exercise testing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: 10 mg ingested orally 1 hour prior to exercise testing
Study: NCT00864682

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 3.3 mL normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine / propofol admixture
Description: lidocaine 50 mg plus propofol 50 mg intravenous (iv)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine pretreatment
Description: lidocaine 50 mg iv under tourniquet-control
Study: NCT00479180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vascugel
Description: One time implant on the day of surgery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vascugel
Description: One time implant on the day of surgery

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: One time implant on the day of surgery
Study: NCT02194179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP XR 400 mg (KCR 25%)
Study: NCT02472548

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV(A)-Alum
Description: Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV(A)-Alum
Description: Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9 % sodium chloride) will be administered intramuscularly.
Study: NCT02069223

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BPD-DS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BPD-DS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BPD-DS
Study: NCT03812471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D volume acquisitions
Description: 2 abdominal volumes 2 thigh volumes 2 head volumes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2D standard measurements and 3D volumes acquisitions
Description: * 1 abdomen circumference measurement~* 1 femur length measurement~* 1 head circumference measurement~* 1 bi-parietal diameter measurement~* 1 abdominal volume~* 1 thigh volume~* 1 head volume
Study: NCT05984472

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Edelweiss prefabricated veneers
Description: Individual Randomized Clinical Trial

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ceram-X Duo SphereTec with U-Veneer
Description: Ceram-X Duo SphereTec with U-Veneer
Study: NCT03321266

Intervention type: DEVICE
Intervention: Cook Biodesign® Fistula Plug
Description: The Cook Biodesign® Fistula Plug is for implantation to reinforce soft tissue for repair of Anorectal fistulas.
Study: NCT03098459

Intervention type: OTHER
Intervention: Non-interventional observational prospective cohort study
Description: Non-interventional observational prospective cohort study
Study: NCT03110094

Intervention type: OTHER
Group type: OTHER
Intervention: Adalimumab
Description: It will be an interventional study with minimal risks and constraints, prospective, mono-centric, in current care. Patient management will not be changed during the study. It will be taken at two different tracking points (M0 and M3) 4 additional tubes and use of surplus articular fluid (M0 and M3).

Intervention type: OTHER
Group type: OTHER
Intervention: Healthy volunteers
Description: Collection of 2 tubes of blood. The values of the quantitative study of lymphocyte subpopulations will be compared to those obtained from healthy blood donors to define the standards used in this study.
Study: NCT01759511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Description: 200 mg/mL administered intravenously biweekly (per original protocol) or 125 mg/mL self-administered subcutaneously every 7 ± 2 days (per protocol amendment 1)
Study: NCT02389985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT02508831

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double upper limb allograft
Description: Patients with bilateral amputation of upper limb will receive a double upper limb allograft
Study: NCT00802087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocodone
Description: Extended Release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocodone
Description: Extended Release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocodone
Description: Extended Release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocodone
Description: Extended Release tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocodone & acetaminophen combination
Description: Immediate Release tablet, hydrocodone and acetaminophen combination product
Study: NCT01161108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fast Release Melatonin (FR MLT)
Description: 3mg capsules of melatonin will be used. The dose of FR MLT will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fast Release Placebo
Description: A matching FR MLT placebo will be compounded by the SickKids research pharmacy.~The dose of Fast Release Placebo will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timed Release Melatonin (TR MLT)
Description: 3 mg capsules will be used.~The dose of TR MLT will be will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timed Release Placebo
Description: A matching TR MLT placebo will be compounded by the SickKids research pharmacy.~The dose of Timed Release Placebo will be will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily.
Study: NCT02650427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 100mg or 200mg or 600mg, daily for 3 weeks ± 7 days
Study: NCT04370223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ozone auto-hemotherapy
Description: ozone auto-hemotherapy
Study: NCT00946478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimecrolimus
Description: 20 AD patients will be given pimecrolimus 1% to apply twice daily for up to three weeks on each lesional site predetermined at baseline. Lesional target site and non-lesional site will be determined at Visit 1.~Two 2 mm biopsies will be obtained from a target AD lesion and non-lesional sites at Visit 2, and Visit 3 (four biopsies each visit).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Vehicle cream
Description: 20 AD patients will be treated with vehicle cream twice daily for up to 3 weeks on each lesional site predetermined at baseline. Lesional target site and non-lesional site will be determined at Visit 1.~Two 2 mm biopsies will be obtained from a target AD lesion and non-lesional sites at Visit 2, and Visit 3 (four biopsies each visit).
Study: NCT05510531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Survival Skills Training
Description: During the course of the DSS sessions, participants receive blood glucose logs, glucose meters; lancets, testing strips and demonstration insulin pens with injecting pillow will only be used in class. In summary, the DSS is focused on increasing knowledge, motivation, and self-efficacy and decreasing diabetes related distress, IMB components relevant to incarcerated persons and proximal to behavior change, through engagement, return demonstrations, skill practice, and positive reinforcement.
Study: NCT02043275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leg training
Description: Lower body resistance training twice per week for one hour each time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm training
Description: Upper body resistance training twice per week for one hour each time.
Study: NCT00887653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: This will be a single arm study where subjects will be given the option to switch from their current regimen to raltegravir at 400mg twice daily.
Study: NCT02008630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal-assisted activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal-assisted therapy
Study: NCT06651437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental dietary educational intervention
Description: At the end of the baseline examination, the Experimental group received a brief dietary education on the health damage due to excess salt consumption and on behavioural methods to gradually reduce dietary intake, for example at home, reduce the consumption of processed foods, do not bring salt shaker on the table, limit the use of condiments with a high sodium content; out of home, both when eating and when shopping, reduce the consumption of processed foods, check nutritional labels and choose products with lower salt content. In addition, written information was provided. All participants will be clinically followed every month, with potential titration of the antihypertensive therapy. After 3 months of follow-up, the baseline measurements will be carried out again. During the entire study period, subjects will be asked to maintain their lifestyle and report using additional medications.
Study: NCT03179696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile-assisted CBT
Description: mCBTn combines the CBT components that target defeatist attitudes from Cognitive Behavioral Social Skills Training (CBSST) group therapy and mobile smartphone interventions from our prior clinical trials research.
Study: NCT00808626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-rBitistatin
Description: Intravenous administration of a single dose (10 mCi, 0.1 ug/kg body weight) of 99mTc-rBitistatin, followed by collection of scintigraphic (planar and SPECT) images at 1 hour and 2-4 hours.
Study: NCT01355926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexible Fiber-based CO2 Laser, Quality of Life forms
Description: . Post operative pain will be measured pre-operatively, and post-operatively on post-operative day (POD) 1, 3, 7, 14, 21 and 28 using a numerical pain rating scale. The secondary outcomes will be measured pre-operatively and post-operatively using the University of Washington Quality of Life questionnaire specific for head and neck version 4 (UW-QOL version 4) and the Performance Status Scale for head and neck cancer (PPS-HN) on days 7, 14 and 28. Other secondary aims will be measured intra-operatively and time to return to work and time to normal diet will be measured during timeframes of POD 1, 3, 7,14, 21 and 28.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrocautery resection and quality of life forms
Description: Post operative pain will be measured pre-operatively, and post-operatively on post-operative day (POD) 1, 3, 7, 14, 21 and 28 using a numerical pain rating scale. The secondary outcomes will be measured pre-operatively and post-operatively using the University of Washington Quality of Life questionnaire specific for head and neck version 4 (UW-QOL version 4) and the Performance Status Scale for head and neck cancer (PPS-HN) on days 7, 14 and 28. Other secondary aims will be measured intra-operatively and time to return to work and time to normal diet will be measured during timeframes of POD 1, 3, 7,14, 21 and 28.
Study: NCT02439190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-986120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study: NCT01422174

Intervention type: PROCEDURE
Intervention: Implantable Cardio Defibrillator (ICD),
Description: Standard ICD implantation (as per clinical decision)
Study: NCT02269748

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tunnel technique with subepithelial connective tissue
Description: After harvesting a connective tissue graft from the palate, the graft is placed under a gingival tunnel prepared over the donor site.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronally advanced flap
Description: After harvesting a connective tissue graft from the palate, the graft is placed under a gingival flap which is repositioned coronally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic Therapy
Description: Ibuprofen 600 mg TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesic Therapy
Description: Ibuprofen 600 mg TID
Study: NCT02932215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorcaserin
Description: Open label

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit Charge HR
Description: This is actually not an intervention- it is a tool to measure activity and sleep; all participants will be receiving one to collect data
Study: NCT01245920

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DFDBA + Bio-Gide Membrane
Description: For patients in the FDBA + membrane group, a layer 4 mm thick of cancellous allograft bone (Puros Cancellous, Zimmer Dental inc., Carlsbad, CA) will be placed over the buccal bone in the area of the implant. A resorbable collagen membrane (Bio-Gide, 13 x 25 mm, Osteohealth, Shirley, NY) will be trimmed to extend 5 mm beyond the implant borders and to cover the implant head. Following membrane placement over the bone graft, the gingival flaps will be closed and sutured with 4-0 Vicryl (Ethicon Inc., Sommerville, NJ) with passive tension flap closure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-FDBA
Description: Patients in the non-FDBA group will have gingival flaps closed with the same suturing technique.
Study: NCT01413061

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subtalar Arthrodesis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subtalar Arthrodesis
Study: NCT02421029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: edetate calcium disodium
Description: All subjects will receive a 250 mL 5% dextrose intravenous infusion over 1 hour that contains 1 gr of edetate calcium disodium
Study: NCT02538328

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Harmonic scapel
Description: different surgical devices used in the obesity surgery
Study: NCT02194179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP XR 400 mg (KCR 20%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP XR 400 mg (KCR 20%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP XR 300 mg (KCR 25%)
Study: NCT01557920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol administration for induction of general anesthesia. Administration will be performed IV, using a Target Controlled Induction Pump.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane will be administered via mask inhalation to achieve anesthesia.
Study: NCT04158778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: Two sessions of MDMA-assisted psychotherapy will take place (session 3 \& 7) within the 10 week course of psychotherapy. An initial dose of 125mg MDMA will be followed by an optional dose of 62.5mg 2 hours later.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Two sessions of MDMA-assisted psychotherapy will take place (session 3 \& 7) within the 10 week course of psychotherapy.
Study: NCT05442437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hUCMSCs
Description: Human umbilical cord mesenchymal stem cell preparation, 100ml/ bag, containing 2.5×107 cells, 5.0×107 cells, 1.0 x 108 cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hUCMSCs
Description: Human umbilical cord mesenchymal stem cell preparation, 100ml/ bag, containing 2.5×107 cells, 5.0×107 cells, 1.0 x 108 cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hUCMSCs
Description: Human umbilical cord mesenchymal stem cell preparation, 100ml/ bag, containing 2.5×107 cells, 5.0×107 cells, 1.0 x 108 cells
Study: NCT02194179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP XR 300 mg (KCR 25%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP XR 300 mg (KCR 20%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP XR 300 mg (KCR 20%)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fat breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fat breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fat breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fat breakfast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP IR 200 mg (Viramune®)
Study: NCT03938740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDV-Insulin Lispro and Insulin Degludec (-40%)
Description: HDV-Insulin Lispro and Insulin Degludec (-40%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDV-Insulin Lispro and Insulin Degludec (-10%)
Description: HDV-Insulin Lispro and Insulin Degludec (-10%)
Study: NCT02538328

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Harmonic scapel
Description: different surgical devices used in the obesity surgery

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ligasure
Description: Bipolar vessel sealing system used in obesity surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ligasure
Description: Bipolar vessel sealing system used in obesity surgery